{
    "nct_id": "NCT02735083",
    "official_title": "Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)",
    "inclusion_criteria": "* Written informed consent obtained prior any study-specific procedure (patient or parent(s) or legal representative)\n* Patient dosed with UCART19 who completed or discontinued early from a sponsored or from any investigator-initiated study that tested UCART19, or patients who were administered UCART19 under a special access scheme (compassionate use);\n* Female patients of childbearing potential and male patients with partners of childbearing potential must continue to use an effective method of birth control as well as their partners for a 12-month duration after the last UCART19 administration.\nHealthy volunteers allowed",
    "exclusion_criteria": "- No exclusion criteria for this study",
    "miscellaneous_criteria": ""
}